Elevance Health, Inc. ( (ELV) ) has released its Q4 earnings. Here is a breakdown of the information Elevance Health, Inc. presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Elevance Health, Inc. is a prominent healthcare company that provides a wide range of health solutions, including medical, pharmacy, and behavioral health services, serving approximately 112 million consumers. The company is known for its commitment to improving healthcare accessibility and affordability.
In its latest earnings report, Elevance Health announced a total operating revenue of $45.0 billion for the fourth quarter of 2024, contributing to a full-year total of $175.2 billion. The company also revealed a quarterly dividend increase of 5% to $1.71 per share, reflecting its ongoing commitment to delivering shareholder value.
Key financial highlights include an increase in operating revenue driven by higher premium yields and growth in the CarelonRx product segment. Despite these gains, the company faced a decline in operating margin due to increased Medicaid medical cost trends. The Health Benefits segment experienced a drop in operating gain, affected by Medicaid membership attrition, while the Carelon segment saw strong revenue growth due to new capabilities and acquisitions.
Looking ahead, Elevance Health’s management projects a positive outlook for 2025, with expected GAAP diluted EPS ranging from $30.40 to $31.10 and adjusted diluted EPS from $34.15 to $34.85. The company aims to continue simplifying the healthcare experience and deploying innovative care models, positioning itself for sustainable growth in the coming years.
